7-Year Efficacy and Safety of iStent inject Trabecular Micro-Bypass in Combined and Standalone Usage
Authors:
Open Access
- 16 February 2024
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 41 (4) , 1481-1495
Abstract
Introduction This study evaluated 7-year effectiveness and safety of second-generation trabecular micro-bypass implantation (iStent inject) either in combination with cataract surgery or as a standalone procedure (Combined or Standalone subgroups, respectively) in eyes with open-angle glaucoma. Methods This prospective, non-randomized, unmasked, longitudinal study included 125 consecutive iStent inject cases of a single surgeon at a large German academic hospital. Patients had considerable preoperative disease burden, with mean intraocular pressure (IOP) of 23.5 mmHg, 84.8% of eyes on ≥ 2 medications, and 38.4% of eyes with prior glaucoma surgery. IOP, medications, adverse events, and secondary surgeries were assessed through 7 years in the Overall cohort and in Combined (n = 81) and Standalone (n = 44) subgroups. Results Over 7-year follow-up, mean IOP decreased by 36.2–40.0% in Overall eyes, 34.1–38.9% in Combined eyes, and 39.5–43.5% in Standalone eyes (p < 0.001 at all timepoints for all groups). Meanwhile, mean medications decreased by 59.3–71.3% in Overall eyes, 57.9–69.0% in Combined eyes, and 62.1–76.2% in Standalone eyes (p < 0.001 at all timepoints in all groups). At last follow-up (mean 77.4 months; 92.8% of patients with last visit at 6 or 7 years), 83.7% of Overall eyes, 82.3% of Combined eyes, and 86.4% of Standalone eyes had achieved ≥ 20% IOP reduction vs preoperative. At last follow-up vs preoperative, 100% of eyes in all groups had the same or lower IOP and 100% had the same or lower medication regimen. Safety outcomes were favorable, with no filtration surgeries and only 4.84% of eyes experiencing clinically significant visual field loss over 7 years of follow-up. Conclusion iStent inject implantation with or without phacoemulsification produced significant and durable 7-year reductions in IOP (~ 34–44% reduction) and medications (~ 58–76% reduction) while preventing filtering surgery in this cohort of patients with relatively high preoperative disease burden. Combined and Standalone cases had similarly favorable effectiveness and safety.Keywords
This publication has 53 references indexed in Scilit:
- Characterization of micro-invasive trabecular bypass stents by ex vivo perfusion and computational flow modelingClinical Ophthalmology, 2014
- Prospective, Unmasked Evaluation of the iStent® Inject System for Open-Angle Glaucoma: Synergy TrialAdvances in Therapy, 2014
- Reduction in Intraocular Pressure after Cataract Extraction: The Ocular Hypertension Treatment StudyOphthalmology, 2012
- Ocular Surface Disease and Quality of Life in Patients With GlaucomaAmerican Journal of Ophthalmology, 2012
- Long-term effects of phacoemulsification with intraocular lens implantation in normotensive and ocular hypertensive eyesJournal of Cataract & Refractive Surgery, 2008
- Three and Five Year Changes in Intraocular Pressures After Clear Corneal Phacoemulsification in Open Angle Glaucoma Patients, Glaucoma Suspects, and Normal PatientsJournal of Glaucoma, 2006
- Persistence and Adherence With Topical Glaucoma TherapyAmerican Journal of Ophthalmology, 2005
- Vision related quality of life and topical glaucoma treatment side effectsHealth and Quality of Life Outcomes, 2003
- Intraocular Pressure Reduction Following Phacoemulsification Cataract Extraction With Posterior Chamber Lens Implantation in Glaucoma PatientsOphthalmic Surgery, Lasers and Imaging Retina, 1999
- Adverse Effects of Topical Antiglaucoma MedicationArchives of Ophthalmology (1950), 1994